# Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct07277452/  
OnCo record `nct07277452` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nimotuzumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.

## Summary

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT07277452 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 156 participants, started 2025-12-10 and due to reach its primary completion in 2028-12-10. Interventions recorded: Nimotuzumab; AG regimen; Placebo. Conditions listed: Pancreatic Cancer, Adult. Primary outcome: disease-free survival (DFS). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: NOTABLE-309
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07277452
- Phase: 2
- Setting: Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
- Sponsor: The First Affiliated Hospital with Nanjing Medical University
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT07277452: https://clinicaltrials.gov/study/NCT07277452

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [Nimotuzumab](https://onco.cc/drugs/nimotuzumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07277452.json